🇺🇸 FDA
Pipeline program

REGN3918

R3918-PNH-1868

Phase 3 small_molecule terminated

Quick answer

REGN3918 for Paroxysmal Nocturnal Hemoglobinuria is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Paroxysmal Nocturnal Hemoglobinuria
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials